vs
Kiniksa Pharmaceuticals International, plc（KNSA）与Rocket Lab Corp（RKLB）财务数据对比。点击上方公司名可切换其他公司
Kiniksa Pharmaceuticals International, plc的季度营收约是Rocket Lab Corp的1.1倍（$202.1M vs $179.7M），Kiniksa Pharmaceuticals International, plc净利率更高（7.0% vs -29.5%，领先36.5%），Kiniksa Pharmaceuticals International, plc同比增速更快（65.0% vs 35.7%），Kiniksa Pharmaceuticals International, plc自由现金流更多（$53.3M vs $-114.2M），过去两年Kiniksa Pharmaceuticals International, plc的营收复合增速更高（59.1% vs 39.2%）
Kiniksa Pharmaceuticals International plc是一家全球性生物制药企业，专注于发现、开发和商业化针对自身免疫性疾病、炎症性疾病及罕见病的靶向治疗药物，服务北美、欧洲、亚洲等主要市场的未被满足的临床需求。
Rocket Lab是公开上市的航空航天制造商及发射服务提供商，旗下Electron轨道火箭主打小型卫星发射，截至2026年1月已成功完成超75次任务，是全球现役发射次数最多的小型运载火箭。公司还开发了Electron的亚轨道改型HASTE用作高超音速技术测试平台，下一代可复用中型运载火箭Neutron目前也在研发中。
KNSA vs RKLB — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $202.1M | $179.7M |
| 净利润 | $14.2M | $-52.9M |
| 毛利率 | 89.6% | 38.0% |
| 营业利润率 | 9.8% | -28.4% |
| 净利率 | 7.0% | -29.5% |
| 营收同比 | 65.0% | 35.7% |
| 净利润同比 | 259.8% | -1.1% |
| 每股收益（稀释后） | $0.18 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $202.1M | $179.7M | ||
| Q3 25 | $180.9M | $155.1M | ||
| Q2 25 | $156.8M | $144.5M | ||
| Q1 25 | $137.8M | $122.6M | ||
| Q4 24 | $122.5M | $132.4M | ||
| Q3 24 | $112.2M | $104.8M | ||
| Q2 24 | $108.6M | $106.3M | ||
| Q1 24 | $79.9M | $92.8M |
| Q4 25 | $14.2M | $-52.9M | ||
| Q3 25 | $18.4M | $-18.3M | ||
| Q2 25 | $17.8M | $-66.4M | ||
| Q1 25 | $8.5M | $-60.6M | ||
| Q4 24 | $-8.9M | $-52.3M | ||
| Q3 24 | $-12.7M | $-51.9M | ||
| Q2 24 | $-3.9M | $-41.6M | ||
| Q1 24 | $-17.7M | $-44.3M |
| Q4 25 | 89.6% | 38.0% | ||
| Q3 25 | 88.8% | 37.0% | ||
| Q2 25 | 88.1% | 32.1% | ||
| Q1 25 | 87.0% | 28.8% | ||
| Q4 24 | 85.4% | 27.8% | ||
| Q3 24 | 82.1% | 26.7% | ||
| Q2 24 | 88.7% | 25.6% | ||
| Q1 24 | 86.7% | 26.1% |
| Q4 25 | 9.8% | -28.4% | ||
| Q3 25 | 13.3% | -38.0% | ||
| Q2 25 | 12.9% | -41.3% | ||
| Q1 25 | 9.6% | -48.3% | ||
| Q4 24 | -15.7% | -38.9% | ||
| Q3 24 | -8.6% | -49.5% | ||
| Q2 24 | -0.1% | -40.7% | ||
| Q1 24 | -20.7% | -46.4% |
| Q4 25 | 7.0% | -29.5% | ||
| Q3 25 | 10.2% | -11.8% | ||
| Q2 25 | 11.4% | -46.0% | ||
| Q1 25 | 6.2% | -49.5% | ||
| Q4 24 | -7.3% | -39.5% | ||
| Q3 24 | -11.3% | -49.6% | ||
| Q2 24 | -3.6% | -39.2% | ||
| Q1 24 | -22.2% | -47.7% |
| Q4 25 | $0.18 | $-0.09 | ||
| Q3 25 | $0.23 | $-0.03 | ||
| Q2 25 | $0.23 | $-0.13 | ||
| Q1 25 | $0.11 | $-0.12 | ||
| Q4 24 | $-0.11 | $-0.11 | ||
| Q3 24 | $-0.18 | $-0.10 | ||
| Q2 24 | $-0.06 | $-0.08 | ||
| Q1 24 | $-0.25 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $414.1M | $1.0B |
| 总债务越低越好 | — | $152.4M |
| 股东权益账面价值 | $567.6M | $1.7B |
| 总资产 | $763.6M | $2.3B |
| 负债/权益比越低杠杆越低 | — | 0.09× |
8季度趋势，按日历期对齐
| Q4 25 | $414.1M | $1.0B | ||
| Q3 25 | $352.1M | $976.7M | ||
| Q2 25 | $307.8M | $688.1M | ||
| Q1 25 | $268.3M | $428.4M | ||
| Q4 24 | $243.6M | $419.0M | ||
| Q3 24 | $223.8M | $442.4M | ||
| Q2 24 | $218.8M | $496.8M | ||
| Q1 24 | $213.6M | $492.5M |
| Q4 25 | — | $152.4M | ||
| Q3 25 | — | $347.0M | ||
| Q2 25 | — | $346.5M | ||
| Q1 25 | — | $345.9M | ||
| Q4 24 | — | $345.4M | ||
| Q3 24 | — | $61.2M | ||
| Q2 24 | — | $64.2M | ||
| Q1 24 | — | $66.8M |
| Q4 25 | $567.6M | $1.7B | ||
| Q3 25 | $535.4M | $1.3B | ||
| Q2 25 | $495.0M | $688.5M | ||
| Q1 25 | $457.5M | $431.3M | ||
| Q4 24 | $438.4M | $382.5M | ||
| Q3 24 | $437.0M | $419.8M | ||
| Q2 24 | $435.1M | $455.2M | ||
| Q1 24 | $431.9M | $478.9M |
| Q4 25 | $763.6M | $2.3B | ||
| Q3 25 | $712.3M | $2.2B | ||
| Q2 25 | $661.1M | $1.6B | ||
| Q1 25 | $599.3M | $1.3B | ||
| Q4 24 | $580.6M | $1.2B | ||
| Q3 24 | $555.3M | $1.2B | ||
| Q2 24 | $542.4M | $1.2B | ||
| Q1 24 | $519.7M | $1.2B |
| Q4 25 | — | 0.09× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.50× | ||
| Q1 25 | — | 0.80× | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | — | 0.15× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $53.9M | $-64.5M |
| 自由现金流经营现金流 - 资本支出 | $53.3M | $-114.2M |
| 自由现金流率自由现金流/营收 | 26.4% | -63.6% |
| 资本支出强度资本支出/营收 | 0.3% | 27.6% |
| 现金转化率经营现金流/净利润 | 3.80× | — |
| 过去12个月自由现金流最近4个季度 | $136.4M | $-321.8M |
8季度趋势，按日历期对齐
| Q4 25 | $53.9M | $-64.5M | ||
| Q3 25 | $33.7M | $-23.5M | ||
| Q2 25 | $28.1M | $-23.2M | ||
| Q1 25 | $22.3M | $-54.2M | ||
| Q4 24 | $18.8M | $-2.4M | ||
| Q3 24 | $-2.2M | $-30.9M | ||
| Q2 24 | $5.2M | $-13.0M | ||
| Q1 24 | $4.0M | $-2.6M |
| Q4 25 | $53.3M | $-114.2M | ||
| Q3 25 | $33.0M | $-69.4M | ||
| Q2 25 | $27.9M | $-55.3M | ||
| Q1 25 | $22.2M | $-82.9M | ||
| Q4 24 | $18.6M | $-23.9M | ||
| Q3 24 | — | $-41.9M | ||
| Q2 24 | — | $-28.3M | ||
| Q1 24 | $3.9M | $-21.8M |
| Q4 25 | 26.4% | -63.6% | ||
| Q3 25 | 18.2% | -44.8% | ||
| Q2 25 | 17.8% | -38.3% | ||
| Q1 25 | 16.1% | -67.6% | ||
| Q4 24 | 15.2% | -18.1% | ||
| Q3 24 | — | -40.0% | ||
| Q2 24 | — | -26.7% | ||
| Q1 24 | 4.9% | -23.5% |
| Q4 25 | 0.3% | 27.6% | ||
| Q3 25 | 0.4% | 29.6% | ||
| Q2 25 | 0.1% | 22.2% | ||
| Q1 25 | 0.1% | 23.4% | ||
| Q4 24 | 0.2% | 16.3% | ||
| Q3 24 | 0.0% | 10.5% | ||
| Q2 24 | 0.0% | 14.4% | ||
| Q1 24 | 0.1% | 20.7% |
| Q4 25 | 3.80× | — | ||
| Q3 25 | 1.83× | — | ||
| Q2 25 | 1.58× | — | ||
| Q1 25 | 2.61× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KNSA
暂无分部数据
RKLB
| Products | $94.0M | 52% |
| Transferred Over Time | $87.3M | 49% |
